Liquidia (NASDAQ:LQDA) Director Sells $6,076,829.28 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 85,062 shares of Liquidia stock in a transaction on Monday, June 15th. The shares were sold at an average price of $71.44, for a total transaction of $6,076,829.28. Following the completion of the sale, the director directly owned 980,073 shares of the company’s stock, valued at approximately $70,016,415.12. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Liquidia Trading Up 3.5%

Shares of NASDAQ:LQDA opened at $71.07 on Friday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $6.32 billion, a PE ratio of 507.68 and a beta of 0.58. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $73.22. The firm has a fifty day moving average price of $52.44 and a 200 day moving average price of $42.03.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% on a year-over-year basis. Analysts expect that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Trading of Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter valued at approximately $25,000. NewEdge Advisors LLC bought a new position in Liquidia in the 2nd quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia during the third quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia during the third quarter worth approximately $34,000. Finally, Covestor Ltd lifted its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research note on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday, June 5th. Finally, Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $60.29.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).